Acción LEGN LEGEND BIOTECH CORPORATION
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Legend Biotech Corporation

Acciones

LEGN

US52490G1022

Tiempo real estimado Cboe BZX
Otros sitios de cotización
 16:43:38 02/05/2024 		Varia. Cinco días. Varia. 1 de enero.
44,64 USD +1,50 % Gráfico intradía de Legend Biotech Corporation -0,07 % -26,23 %
22/04 CARVYKTI® (ciltacabtagene autoleucel) de Legend Biotech Corporation aprobado por la Comisión Europea para el tratamiento de segunda línea de pacientes con mieloma múltiple recidivante y refractario CI
19/04 La FDA estadounidense obliga a actualizar las etiquetas de las terapias CAR-T contra el cáncer RE

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
US FDA mandates label updates on CAR-T cancer therapies
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval
Innovative personalised immunotherapy approved for multiple myeloma
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
U.S. FDA approves expanded use of J&J's cancer cell therapy
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
U.S. FDA allows expanded use of Bristol Myers' cell therapy
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report
Legend Biotech Files Mixed-Securities Shelf Registration
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción LEGN
  4. Noticias Legend Biotech Corporation
  5. Otros idiomas